您的购物车当前为空
别名 森利珠单抗, CDP-571, BAY-103356
Senlizumab 是一种在 CHO 细胞中表达的人源单克隆抗体,特异性靶向 TNFSF2 (肿瘤坏死因子-α, TNF-α)。Senlizumab 由 huIgG4SP 型重链和 huκ 型轻链组成,预测分子量 (MW) 为 146.9 kDa。通过特异性结合 TNF-α,Senlizumab 能够阻断其与 TNF 受体(TNFR)的相互作用,从而抑制下游炎症信号传导及细胞因子的释放。Senlizumab 适用于自身免疫性疾病及炎症机制的相关研究。其同型对照可参考 Human IgG4 kappa, Isotype Control (HY-P99003)。
Senlizumab 是一种在 CHO 细胞中表达的人源单克隆抗体,特异性靶向 TNFSF2 (肿瘤坏死因子-α, TNF-α)。Senlizumab 由 huIgG4SP 型重链和 huκ 型轻链组成,预测分子量 (MW) 为 146.9 kDa。通过特异性结合 TNF-α,Senlizumab 能够阻断其与 TNF 受体(TNFR)的相互作用,从而抑制下游炎症信号传导及细胞因子的释放。Senlizumab 适用于自身免疫性疾病及炎症机制的相关研究。其同型对照可参考 Human IgG4 kappa, Isotype Control (HY-P99003)。

| 产品描述 | Senlizumab is a human monoclonal antibody expressed in CHO cells that specifically targets TNFSF2 (Tumor Necrosis Factor-alpha, TNF-α). It features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight of 146.9 kDa. Senlizumab neutralizes the biological activity of TNF-α by blocking its interaction with TNF receptors, thereby inhibiting downstream pro-inflammatory signaling pathways. It serves as a valuable tool for research into autoimmune and inflammatory diseases. The recommended isotype control is Human IgG4 kappa, Isotype Control (HY-P99003). |
| 别名 | 森利珠单抗, CDP-571, BAY-103356 |
| 反应种属 | Human |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG4 (S228P) |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| Uniprot ID | |
| 靶点 | TNFSF2/TNFa |
| CAS No. | 336128-48-4 |
| 存储 |
对于不同动物的给药剂量换算,您也可以参考 更多